THE FIRST AND ONLY DIABETIC DES RANDOMIZED TRIAL DESIGNED FOR SUPERIORITY: DIAB8

WE ARE ALVIMEDICA

WORLD LEADING QUALITY

LIVING INNOVATION

BETTER OUTCOMES FOR PATIENTS

Alvimedica, officially unveiled the details of the Diab8 study, the first diabetic Drug-Eluting Stent (DES) randomized trial, during the Annual Meeting of EuroPCR 2018.
News

A global manufacturer of unique interventional medical devices, harnessing the power of innovation to improve our patient’s quality of life. We tackle today’s toughest patients clinical conditions by creating innovative products.
About

We create the highest quality products, trusted by leading professionals around the world.
About

Our driving passion is to improve the quality of life through innovative technology, creating a better future by investing in both clinical research and product development.
Products

Alvimedica is committed to improving patient outcomes, as well as tackling global issues such as Diabetes, which we are 100% committed to defeating.
Products

PRODUCTS

DIABETES

WORKING FOR
DIABETES
PROJECTS

Diabetes is a number of diseases that involve
problems with hormone insulin.
Normally...

NEWS

The First and Only Diabetic DES Randomized Trial Designed for Superiority: DIAB8

Alvimedica, officially unveiled the details of the Diab8 study, the first diabetic Drug-Eluting Stent (DES) randomized trial, during the Annual Meeting of EuroPCR 2018

Alvimedica to strengthen manufacturing footprint for the future

Istanbul, Turkey, October 19, 2017- Alvimedica, global medical technologies group, pleased to announce taking the first step for the opening of its third factory, the newest production facility, located in Çatalca, Istanbul.

EuroPCR 2017 Wrap-Up Interview

Challenges in diabetic patients: EVOlving PCI's clinical outcome through innovative technology

DISCOVER